Skip to main content

You will need to login before you can apply for a job.

Manager, AAV Process Development

Employer
Precision BioSciences, Inc.
Location
Durham, NC
Start date
Nov 14, 2024
View more categoriesView less categories
Discipline
Engineering, Manufacturing & Production, Process
Required Education
Bachelors Degree
Position Type
Full time
Hotbed
Bio NC

Job Details

Summary

The Manager, AAV Process Development will lead a team of experienced AAV Process Development engineers progressing pre-IND and clinical-stage AAV gene editing programs toward commercialization. Under this person’s leadership, the AAV Process Development team will continue refining and advancing a best-in-class AAV drug substance and drug product manufacturing platform for PBGENE drug candidates. The ideal candidate for this position is an experienced Scientist/Engineer with a strong background in viral vector biology and manufacturing, and prior people management experience. The candidate should be proficient in upstream and downstream process development, process scale-up, and tech transfer to GMP manufacturing. This person will be a hands-on manager, participating in lab activities and batch execution while handling day-to-day leadership responsibilities for a team of Research Associates and Engineers. This leader will collaborate across functional areas, working closely with MS&T, Analytical Development, Quality Assurance, and Research leads to ensure project advancement, rapid and best-in-class execution, and clear communication of challenges and opportunities.

Essential Duties and Responsibilities

Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions of this position. This list contains the major duties and requirements of the job and is not all-inclusive. Incumbent(s) may be expected to perform role-related duties other than those contained in this document.

  • Manage a team of process engineers developing best-in-class AAV manufacturing processes
  • Develop and clearly communicate team goals, aligned with CMC and corporate objectives
  • Manage and mentor team members; provide feedback and coaching for individual development
  • Manage the daily operation of the team, including delegation of tasks
  • Provide hands-on technical oversight of development activities
  • Design and execute AAV process optimization and characterization studies, providing expertise and presenting results in cross-functional interactions
  • Contribute to the definition of critical quality attributes and manufacturing control strategies
  • Apply Quality by Design principles to build process and product understanding
  • Work closely with MS&T to:
  • Support technology transfer activities to external CDMO partners
  • Provide technical expertise and assist in the review of Batch Records, SOPs, Change Controls, manufacturing campaign summary reports and process validation strategy documents
  • Lead technical troubleshooting, and support manufacturing investigations, root cause analyses, CAPAs, impact and risk assessments and change controls
  • Work with Analytical Development to develop fit-for-purpose assays and analytical tools to improve process and product understanding
  • Develop and diligently manage annual capital and operating budgets
  • Lead the planning and production effort for IND-enabling batches at the 50L and 200L scale
  • Contribute to the writing and review of US and ex-US regulatory filings and updates
  • Ensure development activities are properly documented to enable seamless use as supporting documentation for filings
  • Develop and provide technical reports supporting process changes and improvements as well as process characterization/pre-validation
  • Remain current with regulatory and scientific advances relevant to the manufacture and process validation of gene therapies
  • Qualifications

    The requirements listed below are representative of the knowledge, skill, and/or ability required to perform this job successfully.

    Required:

    • BS in Chemical Engineering, Biochemistry, Bioengineering, or similar discipline with a minimum of 8+ years of industrial bioprocess development experience, or equivalent combination of education & experience
    • Proven hands-on lab experience developing scalable viral vector manufacturing processes
    • Excellent interpersonal, verbal and written communication skills
    • Ability to think critically, and demonstrated troubleshooting and problem-solving skills
    • Prior experience managing people
    • Strong organizational skills and the ability to manage many projects simultaneously
    • Proficiency with Microsoft Office software suite, and DOE/statistical software such as JMP or Minitab

    Preferred:

    • MS or PhD in Chemical Engineering, Biochemistry, Bioengineering, or similar discipline
    • Strong familiarity with AAV biology and manufacturing strategies
    • Proven ability to collaborate effectively across functions and levels, especially with colleagues in MS&T, Analytical Development, and Research functions
    • Experience writing and reviewing regulatory submissions (INDs, CTAs/IMPD-Qs, or BLAs)
    • Familiarity with QbD development framework

    Travel Requirements

    • This position may require minimal travel (up to 10%)

    Location

    · This is an office-based position associated with the main headquarters in Durham, NC.

    Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. This isn’t just a statement supporting the products that we’re developing – it’s a statement that speaks to our collective desire to do our part in improving the lives of those around us. ARCUS is a highly specific and versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is developing in vivo gene correction therapies for genetic diseases. Our team includes pioneers in genome editing, leaders in business, and a full staff of talented and committed people who are excited to be a part of medical and scientific breakthroughs. For additional information, please visit www. precisionbiosciences.com

    Precision BioSciences actively fosters an inclusive environment to ensure we attract and retain the best talent; we value diversity of life experiences and perspectives; and we encourage innovation in pursuit of our mission. We provide equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity or expression, national origin, age, disability, genetic information, marital status, amnesty, or status as a covered veteran in accordance with applicable federal, state and local laws. Precision BioSciences complies with applicable state and local laws governing non-discrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.

    Company

    Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com

    Stock Symbol: DTIL

    Stock Exchange: NASDAQ

    Company info
    Website
    Phone
    919-314-5512
    Location
    302 East Pettigrew Street
    Durham
    North Carolina
    27701
    United States

    Get job alerts

    Create a job alert and receive personalized job recommendations straight to your inbox.

    Create alert